Immunomedics Stock News

Immunomedics, Inc. (NASDAQ:IMMU) reached a new 52-week high on Friday . The company traded as high as $35.65 and last traded at $35.62, with a volume of 2104197 shares. The stock had previously closed

Is (IMMU) Outperforming Other Medical Stocks This Year?

Immunomedics (NASDAQ:IMMU) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a report released on Friday, BidAskClub reports. A number of other analysts have also recently

The offering raised $2.2 billion for Royalty Pharma’s business of acquiring royalty rights in drugs from the research institutions that developed them and investing in clinical trials for new treatm

Magenta Therapeutics (Nasdaq: MGTA) and Beam Therapeutics (Nasdaq: BEAM) today announced a non-exclusive research and clinical collaboration agreement

Innovent Bio formed a far-reaching R&D collaboration with Roche that has a potential value of over $2 billion. Burning Rock Biotech, a company that offers preci

BNP Paribas Arbitrage SA raised its holdings in Immunomedics, Inc. (NASDAQ:IMMU) by 271.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (

Economic optimism has broadened the market rally. Small caps had lagged significantly and are now catching-up as they narrow the performance gap. The Federal Re

UBS Group AG trimmed its holdings in shares of Immunomedics, Inc. (NASDAQ:IMMU) by 76.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 40,201 shar

The company, which invests in royalties on approved and late-stage biopharmaceutical products, filed for the biggest IPO of the year thus far. The news follows biotech's biggest IPO of 2020, China-bas

In this article you are going to find out whether hedge funds think Immunomedics, Inc. (NASDAQ:IMMU) is a good investment right now. We like to check what the smart money thinks first before doing ext

NEW YORK, June 05, 2020 -- Apyx Medical Corporation (APYX) Lifshitz Law Firm, P.C. announces investigation into possible breaches of fiduciary duty by certain of Apyx’s.

Immunomedics (IMMU) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CBC Group-incubated Everest Medicines Completes $310M Series C Round – China Money Network - China Money Network